epiglucan has been researched along with Pseudomonas-Infections* in 3 studies
3 other study(ies) available for epiglucan and Pseudomonas-Infections
Article | Year |
---|---|
The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice.
Micafungin inhibits biofilm formation by impeding 1,3-β-D-glucan synthesis in Candida albicans. Since Pseudomonas aeruginosa also has 1,3-β-D-glucan in its cell wall, this study assessed the effects of antibacterial agents in vitro and in vivo on micafungin-treated biofilm-forming P. aeruginosa isolates. After treatment with micafungin as well as with a panel of four antibacterial agents, biofilm production was significantly reduced as measured by spectrophotometry. The relative mRNA transcription levels for the genes encoding pellicles (pelC) and cell wall 1,3-β-D-glucan (ndvB), which were measured by quantitative reverse transcription PCR (qRT-PCR), significantly decreased with micafungin treatment. In vivo, the survival rates of P. aeruginosa-infected BALB/c mice significantly increased after combined treatment with micafungin and each of the antibacterial agents. Of these treatments, the combination of micafungin with levofloxacin had the highest survival rate; this combination was the most effective treatment against P. aeruginosa-induced infection. Topics: Animals; Anti-Bacterial Agents; beta-Glucans; Biofilms; Candida albicans; Drug Therapy, Combination; Echinocandins; Levofloxacin; Lipopeptides; Male; Micafungin; Mice; Mice, Inbred BALB C; Pseudomonas aeruginosa; Pseudomonas Infections; Survival Analysis | 2016 |
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity.
Topics: Bacteremia; beta-Glucans; Cross Reactions; Diagnosis, Differential; False Positive Reactions; Humans; Mycoses; Proteoglycans; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
A new method for the quantification of beta-glucan in plasma and its application in the diagnosis of postoperative infection.
In order to correctly diagnose and treat severe postoperative infections, it may be critical to detect and differentiate between endotoxin derived from Gram-negative bacteria and/or beta-glucan derived from fungi. In addition to the chromogenic assay, the turbidimetric kinetic assay has been performed for the quantification of endotoxin in plasma using Limulus amebocyte lysate as previously reported. However, it is also known that beta-glucan triggers the coagulation of Limulus amebocyte lysate. In the present study, the differentiation of beta-glucan from endotoxin and its clinical application were studied. Endotoxin was able to be inactivated in plasma using one-tenth dilution by 10 per cent ethanol or distilled water, followed by heating at 100 degrees C for 120 min, without affecting the activity of coexisting beta-glucan. The treated sample was then subjected to the turbidimetric kinetic assay using Toxinometer ET-201. Using this method, as little as 30 pg/ml of beta-glucan in the plasma may be assayed separately, with the amount of circulating beta-glucan in the plasma of normal subjects being less than 50 pg/ml. On the other hand, in patients with a fungal infection, the amount of beta-glucan in their plasma was elevated significantly. Clinically, beta-glucanemia may often occur in severe postoperative infection even if fungi are not detected. Topics: beta-Glucans; Candidiasis; Endotoxins; Escherichia coli Infections; Glucans; Humans; Mycoses; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Values; Salmonella Infections; Surgical Wound Infection | 1990 |